abstract |
The present invention is concerned with chemokine derived analogs, including SDF-1 and/or SDF-1/MIP1α hybrid analogs, that are useful for the treatment of a variety of diseases and disorders, and as an adjunct to the treatment of a variety of diseases and disorders. A therapeutically effective amount of the chemokine analog may be administered to a patient in need of such treatment. |